.jpg?format=webp&width=780)
Severe hypoglycaemia (SH) remains common in type 1 diabetes (T1D). SH can be treated with glucagon, but its cost, short shelf life and difficulty of preparation and administration make glucagon underused. Dasiglucagon is a glucagon analogue available in a ready‐to‐use aqueous formulation. This is an integrated analysis of the safety and efficacy of dasiglucagon to treat SH in T1D. Dasiglucagon had a similar safety and tolerability profile to reconstituted glucagon. In the placebo‐controlled data sets, no serious adverse events (AEs), AEs leading to withdrawal from the trial or deaths were reported. The most common causally-related AEs were nausea (56.5%) and vomiting (24.6%). The broad pool safety analysis showed similar results. Dasiglucagon efficacy in time to plasma glucose recovery from insulin‐induced SH was similar to reconstituted glucagon and superior to placebo. Median recovery time was consistent across all placebo‐controlled trial subgroups. Dasiglucagon was well tolerated and effective as a rapid rescue agent for insulin‐induced SH in people with T1D.
Like
Save
Share